ACA
MDGL icon

Atlas Capital Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Atlas Capital Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$267 – 949
2024
Q1 		$267 Buy
+1
New +$236 ﹤0.01% 866

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Atlas Capital Advisors's MDGL Position: Q2 2024 in Review

Atlas Capital Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2024, closing a stake of 1 share — an estimated $267 sold.

Atlas Capital Advisors first reported a position in MDGL in Q1 2024 and held it in 1 quarter. The position peaked at $267 in Q1 2024. 257 funds tracked by Wall St. Rank hold MDGL as of Q2 2024.

  • Atlas Capital Advisors reported no remaining Madrigal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Atlas Capital Advisors sold 1 Madrigal Pharmaceuticals share in Q2 2024, an estimated $267.
  • Atlas Capital Advisors first reported a position in Madrigal Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Atlas Capital Advisors's Madrigal Pharmaceuticals position peaked at $267 in Q1 2024.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2024.

Based on Atlas Capital Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.